U.S. Exempts U.K. Pharmaceuticals, Medical Technology From Tariffs

The U.S. government announced on December 1 that it had reached an agreement in principle with the United Kingdom to carve out medicines and medical technology from tariff measures enacted under two U.S. statutes. The exemption will cover U.K. origin finished pharmaceuticals, active pharmaceutical ingredients and medical technologies, and will apply to tariffs already in place as well as to any imposed in the future under the relevant laws.

U.S. officials described the measure as primarily driven by public health concerns, saying coordination among the Office of the U.S. Trade Representative, the Department of Commerce and the Department of Health and Human Services was intended to prevent tariff measures from disrupting supply chains for essential drugs and health technologies. The administration emphasized that ensuring predictable cross border trade in critical medical goods was central to national preparedness and day to day access for patients.

As part of the deal the United Kingdom reportedly agreed to increase the net price paid by its National Health Service for new medicines by 25 percent. British pharmaceutical companies also committed to maintain and expand investments in the United States. U.S. trade and health officials framed those concessions as balancing U.S. policy concerns about industrial competitiveness and fair market access with the imperative to keep medicines flowing.

Industry groups welcomed the announcement as a way to reduce the risk that tariff driven costs and administrative hurdles would interrupt production and distribution. For manufacturers and hospital systems that operate integrated global supply chains, the exemption could lower the immediate risk of shortages and support planned investments in U.S. research and manufacturing capacity.

Public health experts said the carve out reflects a willingness by U.S. policymakers to make sector specific exceptions when national health is at stake, but they also warned that such exceptions can create uneven treatment across industries and complicate broader trade policy goals. For communities that rely on affordable medicines, preventing tariff related price shocks is a tangible benefit. At the same time the increase in costs for the U.K. health system raises equity questions about who ultimately bears the burden of trade negotiations.

Health policy analysts noted the deal could accelerate bilateral cooperation on biopharmaceutical research, clinical trials and advanced manufacturing, but they cautioned that the terms will be scrutinized on both sides of the Atlantic. In the United States, lawmakers who have pushed for greater domestic manufacturing of pharmaceuticals and medical devices may press for stronger commitments from industry on production and job creation. In Britain, ministers must reconcile higher net prices for new drugs with political commitments to protect patients and manage public budgets.

The agreement in principle is a demonstration of how trade policy is increasingly being shaped by public health priorities, while also laying bare the trade offs that governments accept to secure uninterrupted access to essential medical goods. Reporting by Andrea Shalal and Susan Heavey; published December 1, 2025.